Document 0083
 DOCN  M9440083
 TI    T-lymphocytes subsets (CD4/CD8 ratio) in breast cancer patients: a
       preliminary study (Meeting abstract).
 DT    9404
 AU    Sevcikova L; Hunakova L; Chorvath B; Turzova M; Boljesikova E;
       Postgraduate Medical Sch., Cancer Res. Inst., Bratislava,;
       Czechoslovakia
 SO    CCPC-93: Second International Cancer Chemo Prevention Conference. April
       28-30, 1993, Berlin, Germany, p. 111, 1993.. Unique Identifier :
       AIDSLINE ICDB/94696790
 AB    T-lymphocyte subsets (CD4/CD8 antigen-positive cells) were determined on
       peripheral blood lymphocytes from 48 patients with breast cancer of
       different stages by flow immunocytometry with the aid of anti-CD4 and
       -CD8 monoclonal antibodies. A broad individual variability of the
       CD4/CD8 ratio among both healthy donors and breast cancer patients was
       observed. The average value of CD4/CD8 ratio decreased in groups as
       follows: healthy donors and Stage I patients, Stage IIA, IIB and Stage
       IV patients. These differences were not statistically significant. The
       difference between healthy donors and Stage IV breast cancer patients
       was statistically significant (p=0.01), if one exceedingly elevated
       value of the CD4/CD8 ratio within the Stage IV group was excluded from
       statistical evaluation. The average CD4/CD8 value in the group of breast
       cancer patients with lymph node or distant metastases was lower than
       that of patients without metastases, but their difference was not
       statistically significant. It is suggested that the determination of
       peripheral blood lymphocyte subsets should be completed with the
       information obtained from the studies of subset determinations in
       lymphoid organs and tumor infiltrating lymphocytes.
 DE    Breast Neoplasms/*IMMUNOLOGY/PATHOLOGY  *CD4-CD8 Ratio  Female  Human
       Lymphatic Metastasis  Neoplasm Metastasis  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).